Trial · NCT01146652
Adverse events998
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 998
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Leukopenia | Blood and lymphatic system disorders | Sarilumab + Disease Modifying Anti-Rheumatic Drugs (DMARD) | 101 | 1,910 | 181 |
| other | Leukopenia | Blood and lymphatic system disorders | Sarilumab Monotherapy | 4 | 111 | 5 |
| other | Neutropenia | Blood and lymphatic system disorders | Sarilumab + Disease Modifying Anti-Rheumatic Drugs (DMARD) | 348 | 1,910 | 786 |
| other | Neutropenia | Blood and lymphatic system disorders | Sarilumab Monotherapy | 18 | 111 | 64 |
| other | Diarrhoea | Gastrointestinal disorders | Sarilumab + Disease Modifying Anti-Rheumatic Drugs (DMARD) | 122 | 1,910 | 153 |
| other | Diarrhoea | Gastrointestinal disorders | Sarilumab Monotherapy | 2 | 111 | 2 |
| other | Injection Site Erythema | General disorders | Sarilumab + Disease Modifying Anti-Rheumatic Drugs (DMARD) | 111 | 1,910 | 751 |
| other | Injection Site Erythema | General disorders | Sarilumab Monotherapy | 0 | 111 | 0 |
| other | Bronchitis | Infections and infestations | Sarilumab + Disease Modifying Anti-Rheumatic Drugs (DMARD) | 215 | 1,910 | 301 |
| other | Bronchitis | Infections and infestations | Sarilumab Monotherapy | 12 | 111 | 19 |
| other | Influenza | Infections and infestations | Sarilumab + Disease Modifying Anti-Rheumatic Drugs (DMARD) | 124 | 1,910 | 160 |
| other | Influenza | Infections and infestations | Sarilumab Monotherapy | 3 | 111 | 4 |
| other | Nasopharyngitis | Infections and infestations | Sarilumab + Disease Modifying Anti-Rheumatic Drugs (DMARD) | 249 | 1,910 | 390 |
| other | Nasopharyngitis | Infections and infestations | Sarilumab Monotherapy | 14 | 111 | 26 |
| other | Pharyngitis | Infections and infestations | Sarilumab + Disease Modifying Anti-Rheumatic Drugs (DMARD) | 110 | 1,910 | 129 |
| other | Pharyngitis | Infections and infestations | Sarilumab Monotherapy | 4 | 111 | 4 |
| other | Upper Respiratory Tract Infection | Infections and infestations | Sarilumab + Disease Modifying Anti-Rheumatic Drugs (DMARD) | 303 | 1,910 | 574 |
| other | Upper Respiratory Tract Infection | Infections and infestations | Sarilumab Monotherapy | 16 | 111 | 21 |
| other | Urinary Tract Infection | Infections and infestations | Sarilumab + Disease Modifying Anti-Rheumatic Drugs (DMARD) | 264 | 1,910 | 428 |
| other | Urinary Tract Infection | Infections and infestations | Sarilumab Monotherapy | 14 | 111 | 22 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01146652/events